Histone deacetylase (HDAC) inhibitor chidamide was recently approved for treating relapsed/refractory peripheral T-cell lymphoma (PTCL) patients. This evidence concerns the gene HDAC9 and peripheral T-cell lymphoma, not otherwise specified.